IDH1 and neoplasm: An IDH1 (R132H)-specific peptide vaccine (IDH-1-vac) inducing a tumor-specific T helper cell response demonstrated efficacy in IDH-1(R132H)+ tumors in preclinical models and a first-in-man clinical trial [71].